Announcements Trials
Browse Landscape Eligibility

Clinical Trials

34 trials
RecentStart dateEnrollment
Gels × Clear all

Phase

Phase 2 19Phase 3 5Phase 4 3Phase 1 3Phase NA 2Phase 1/2 1

Status

Completed 23Recruiting 4Terminated 3Unknown 2Withdrawn 1Active not recruiting 1

Sponsor Class

INDUSTRY 18OTHER 15OTHER_GOV 1

Study Type

Interventional 33Observational 1

Sponsor

Cancer Type

Dermatologic 18Head & Neck 4Lymphoid 3Gastrointestinal 2Breast 2Thoracic 1Gynecologic 1Genitourinary 1

Conditions

Keratosis, Actinic 12Head and Neck Neoplasms 3Condylomata Acuminata 3Neoplasms 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Exanthema 2Colorectal Neoplasms 2Breast Neoplasms 2Wounds and Injuries 1Warts 1Virus Diseases 1Usual Type Vulval Intraepithelial Neoplasia (uVIN) 1Urologic Neoplasms 1Urologic Diseases 1Urinary Bladder Neoplasms 1Urinary Bladder Diseases 1Squamous Intraepithelial Lesions 1Skin Neoplasms 1Sexually Transmitted Diseases 1Radiodermatitis 1Parapsoriasis 1Papillomavirus Infections 1Non-Muscle Invasive Bladder Neoplasms 1Non-Melanoma Skin Cancers 1Non-Melanoma Skin Cancer (NMSC) 1Lymphoma, Follicular 1Keratosis, Seborrheic 1Hypogonadism 1Hemangioma, Cavernous 1

Interventions

Cisplatin 3176Cyclophosphamide 3172Carboplatin 2955Radiotherapy 2771Paclitaxel 2705Gemcitabine 2549pembrolizumab 2368Bevacizumab 2192Docetaxel 2190Fluorouracil 1837Capecitabine 1815Oxaliplatin 1723Dexamethasone 1592Nivolumab 1575Doxorubicin 1500Rituximab 1480Magnetic Resonance Spectroscopy 1365Etoposide 1341Irinotecan 1240Leucovorin 1215Drug Therapy 1189Cytarabine 1126Pemetrexed 1067fludarabine 1035Specimen Handling 985Vincristine 964Prednisone 940Cetuximab 938Trastuzumab 936Lenalidomide 932

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements
NCT04301765 2026-03-31

TEMEC

Seattle Institute for Biomedical and Clinical Research

Phase 2 Recruiting
230 enrolled

Eunuchism, Fatigue, Hypogonadism, Neoplasms

NCT07201376 2026-02-06

PPIX

Dartmouth-Hitchcock Medical Center

Recruiting
125 enrolled
Dermatologic

Non-Melanoma Skin Cancer (NMSC)

NCT04570956 2026-01-23

Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer Risk

Mayo Clinic

Phase 2 Terminated
65 enrolled
Breast

Breast Carcinoma In Situ, Breast Neoplasms

NCT04173247 2025-03-17

Study of KeraStat Cream for Radiation Dermatitis During Head and Neck Radiotherapy

Wake Forest University Health Sciences

Phase NA Completed
28 enrolled 12 charts
Head & Neck

Head and Neck Neoplasms, Radiodermatitis

NCT06879366 2025-03-17

Evaluation of the Efficacy of Aloe-Vera el Versus Bezydamine Hydrochloride in the Prevention of Radiation Induced Oral Mucositis A Randamized Controlled Clinical Trial

October 6 University

Phase 4 Completed
40 enrolled
Head & Neck

Head and Neck Cancer Patients Treated With Radiotherapy

NCT01803477 2025-02-24

Safety and Dose Finding Study of New Vehicle Formulations Containing Ingenol Mebutate to Treat Actinic Keratosis on the Forearm

LEO Pharma

Phase 1/2 Completed
37 enrolled
Dermatologic

Keratosis, Actinic

NCT05387525 2025-02-11

AKtive

Almirall, S.A.

Phase 4 Active not recruiting
447 enrolled
Dermatologic

Keratosis, Actinic

NCT06745999 2024-12-24

Cryotherapy in Combination with Red Light PDT for Actinic Keratosis of Full Face

Psoriasis Treatment Center of Central New Jersey

Phase 4 Unknown
40 enrolled
Dermatologic

Keratosis, Actinic

NCT06577311 2024-08-29

Evaluating the Use of Photodynamic Therapy to Treat Facial Cutaneous Squamous Cell Carcinoma in Situ (SCCis)

The Center for Clinical and Cosmetic Research

Phase 2 Recruiting
20 enrolled
DermatologicGynecologic

Squamous Intraepithelial Lesions, Carcinoma, Squamous Cell, Skin Neoplasms

NCT06409195 2024-05-10

A Trial to Study the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratoses and Non-Melanoma Skin Cancers

DermBiont, Inc.

Phase 2 Recruiting
50 enrolled
Dermatologic

Non-Melanoma Skin Cancers

NCT05800834 2023-09-28

MorphineGEL

Instituto Nacional de Cancer, Brazil

Phase 2 Unknown
106 enrolled
BreastHead & Neck

Cancer Pain, Breast Neoplasms, Head and Neck Neoplasms, Wounds and Injuries

NCT03546166 2023-07-21

PICABAS

Centre Hospitalier Universitaire de Nice

Phase 2 Completed
24 enrolled
Dermatologic

Carcinoma, Carcinoma, Basal Cell

NCT02462187 2023-04-06

Topical NVN1000 for the Treatment of External Genital and Perianal Warts

Novan, Inc.

Phase 2 Completed
108 enrolled 19 charts

Condylomata Acuminata

NCT01874860 2022-12-01

Skin Rash Study Before Chemotherapy in Colorectal & Head and Neck Cancer Patients

University of Louisville

Phase 2 Completed
24 enrolled
GastrointestinalHead & Neck

Head and Neck Neoplasms, Colorectal Neoplasms

NCT03380026 2021-11-24

MIDAS

Rochester Skin Lymphoma Medical Group, PLLC

Phase 2 Completed
28 enrolled 8 charts
DermatologicLymphoid

Dermatitis, Contact, Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous

NCT03826550 2019-02-01

Therapeutic Equivalence of Diclofenac Sodium Gel 3% vs Solaraze ® in the Treatment of Actinic Keratosis

Encube Ethicals Pvt. Ltd.

Phase 3 Completed
655 enrolled
Dermatologic

Keratosis, Actinic

NCT02724254 2018-07-20

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to 16 Weeks in Condyloma Patients

Vaxart

Phase 2 Completed
218 enrolled

Condylomata Acuminata, Sexually Transmitted Diseases, Virus Diseases, Papillomavirus Infections

NCT03508856 2018-04-26

Clinical and Histologic Evaluation of Picato 0.15% Gel in the Cosmetic Improvement of Photoaged Skin

Skin Laser & Surgery Specialists

Phase NA Completed
23 enrolled
Dermatologic

Keratosis, Actinic

NCT02596074 2017-08-03

Pharmacodynamics, Safety/Tolerability and Efficacy of Topical Omiganan in Patients With uVIN

Maruho Co., Ltd.

Phase 2 Completed
12 enrolled

Usual Type Vulval Intraepithelial Neoplasia (uVIN)

NCT02748902 2017-07-17

Exploratory Study of Efficacy and Safety of Ingenol Mebutate 0.05% Gel for Common Warts on the Hands.

TCR Medical Corporation

Phase 1 Completed
16 enrolled

Warts

NCT02307487 2017-06-16

Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel and MMC in NMIBC Patients

UroGen Pharma Ltd.

Phase 2 Completed
14 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Neoplasms, Urologic Diseases, Urologic Neoplasms

NCT02796066 2017-04-26

TSN2898-201 Safety and Efficacy of TSN2898 in the Treatment of Acne Vulgaris

Thesan Pharmaceuticals, Inc.

Phase 2 Withdrawn
Lymphoid

Acne Vulgaris, Lymphoma, Follicular

NCT02849262 2017-03-31

Pharmacodynamics, Safety and Efficacy of Topical Omiganan in Patients With External Genital Warts

Maruho Co., Ltd.

Phase 2 Completed
24 enrolled

Condylomata Acuminata

NCT02145884 2017-02-13

Topical Timolol Gel for the Treatment of Infantile Hemangiomas

Rady Children's Hospital, San Diego

Phase 2 Completed
26 enrolled

Hemangioma, Hemangioma, Cavernous

NCT01931150 2017-01-13

Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT

Memorial Sloan Kettering Cancer Center

Phase 3 Completed
11 enrolled 7 charts
Gastrointestinal

Exanthema, Colorectal Neoplasms

NCT00850681 2015-09-09

A Study to Evaluate the Photoallergic Potential of PEP005 (Ingenol Mebutate) Gel, 0.01% in Healthy Volunteers

Peplin

Phase 1 Completed
50 enrolled
Dermatologic

Keratosis, Actinic

NCT00850811 2015-09-09

A Study to Evaluate the Photoirritation Potential of PEP005 (Ingenol Mebutate) Gel, 0.01% in Healthy Volunteers

Peplin

Phase 1 Completed
30 enrolled
Dermatologic

Keratosis, Actinic

NCT00742391 2015-03-06

A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations

Peplin

Phase 3 Completed
255 enrolled 9 charts
Dermatologic

Keratosis, Actinic

NCT00852137 2015-03-06

A Study to Evaluate the Pharmacokinetics of PEP005 (Ingenol Mebutate) Gel, 0.05%, When Applied in a Maximal Use Setting to the Dorsal Aspect of the Forearm in Patients With Actinic Keratosis

Peplin

Phase 2 Completed
16 enrolled 9 charts
Dermatologic

Keratosis, Actinic

NCT00915551 2015-03-06

A Multi-Center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)

Peplin

Phase 3 Completed
278 enrolled 9 charts
Dermatologic

Keratosis, Actinic

NCT00942604 2015-03-06

A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations

Peplin

Phase 3 Completed
203 enrolled 8 charts
Dermatologic

Keratosis, Actinic

NCT00322296 2013-04-16

Phase II Trial to Evaluate the Efficacy of Topical Bexarotene Gel in Patients With Parapsoriasis

Fox Chase Cancer Center

Phase 2 Terminated
8 enrolled
DermatologicLymphoid

Mycosis Fungoides, Parapsoriasis, Lymphoma, T-Cell, Cutaneous

NCT00343187 2011-05-30

A Phase II Study of ACZONE™ (Dapsone) Gel, 5% As a Treatment For Tarceva® (Erlotinib)Related Rash

Allergan

Phase 2 Terminated
2 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Exanthema

NCT01214564 2011-01-25

Study to Evaluate the Safety and Efficacy of PEP005(Ingenol Mebutate) Gel, 0.05%, in Patients With Seborrhoeic Keratosis

Peplin

Phase 2 Completed
24 enrolled
Dermatologic

Keratosis, Seborrheic, Keratosis, Actinic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡